CLSN is going to prove him wrong based on positive post hoc positive data from failed p3 trial, imo. Trial design was flawed. AF & anonymous cohorts have been extremely aggressive in their efforts to discredit CLSN mgt. & their science. The co. trades for a dollar & change and any update concerning the trial, global conferences, etc. is attacked by potent short positions. Makes one wonder why.